PT-141

Sexual Health Subcutaneous Injectable / Nasal Spray

PT-141 (Bremelanotide) is a melanocortin receptor agonist that works on the central nervous system to increase desire — FDA-approved for women's sexual dysfunction and used off-label in men. Unlike vascular medications like Viagra or Cialis, PT-141 acts on arousal itself, not just blood flow.

Best for: HSDD (low desire), SSRI-induced sexual dysfunction, post-menopausal libido support.

Book Consult→ Get discounts with memberships →

Frequently Asked

What clients want to know about PT-141

The questions, answered.

Increases sexual desire at the central nervous system level.
Works on arousal — not just blood flow — useful where vascular drugs fall short.
Helpful for SSRI-induced sexual dysfunction in both sexes.
Supports post-menopausal libido.
FDA-approved for HSDD in pre-menopausal women.
Effective within hours rather than requiring continuous dosing.

Melanocortin-4 receptor activation in the hypothalamus.
Central nervous system desire pathway — distinct from vascular response.
Dopamine release in reward circuits.
Independent of testosterone or estrogen levels.

Weeks 1–2: Acute effect within 30–60 minutes per dose; no cumulative use needed.
Weeks 4–6: Consistent effect across uses; psychological comfort with the protocol grows.
Weeks 8–12: Many clients use situationally indefinitely; not a daily commitment.

Nausea — most common side effect, especially first dose.
Flushing — face and chest warmth.
Headache — usually mild.
Transient blood pressure changes — monitored at first dose.
Darkening of moles or skin spots — uncommon but worth tracking.

Dose 30–60 minutes before intimacy for optimal timing.
Eat a light meal beforehand — reduces nausea risk.
Start at a low dose to gauge sensitivity.
Stay hydrated.
Pair with relaxation/connection time — PT-141 amplifies desire that's already accessible.

Uncontrolled hypertension or significant cardiovascular disease.
Pregnancy or breastfeeding.
Known peptide hypersensitivity.
History of melanoma — discuss with provider given melanocortin pathway.

Important Note The FDA's position on peptides continues to evolve. Availability of specific compounds may change, and not all peptides discussed are currently offered at every visit. Book a consultation with our provider team to discuss your goals, current options, and what's appropriate for you.

PT-141

The questions, answered.

Layered with intention.

Precision protocols.
Designed around you.

PT-141

The questions, answered.

Layered with intention.

Precision protocols.Designed around you.

Precision protocols.
Designed around you.